Javed Butler, Sanjiv J Shah, Mark C Petrie, Barry A Borlaug, Steen Z Abildstrøm, Melanie J Davies, G Kees Hovingh, Dalane W Kitzman, Daniél Vega Møller, Subodh Verma, Mette Nygaard Einfeldt, Marie L Lindegaard, Søren Rasmussen, Walter Abhayaratna, Fozia Z Ahmed, Tuvia Ben-Gal, Vijay Chopra, Justin A Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtěch Melenovský, Bela Merkely, Julio Núñez, Eduardo Perna, Morten Schou, Michele Senni, Kavita Sharma, Peter van der Meer, Dirk Von Lewinski, Dennis Wolf, Mikhail N Kosiborod
BACKGROUND: In the STEP-HFpEF (NCT04788511) and STEP-HFpEF DM (NCT04916470) trials, the GLP-1 receptor agonist semaglutide improved symptoms, physical limitations, bodyweight, and exercise function in people with obesity-related heart failure with preserved ejection fraction. In this prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials, we aimed to provide a more definitive assessment of the effects of semaglutide across a range of outcomes and to test whether these effects were consistent across key patient subgroups...
April 4, 2024: Lancet